Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 1/7/2026

Management of Antidepressant-Induced Orgasmic Dysfunction

Treatment Recommendations

  • The American Urological Association recommends adding a phosphodiesterase-5 inhibitor (sildenafil or tadalafil) as adjunctive therapy for antidepressant-induced sexual dysfunction, including orgasmic difficulties, with a strength of evidence supported by multiple randomized controlled trials 1, 2
  • PDE5 inhibitors improve not just erectile function but also orgasmic intensity and ability to achieve orgasm in men on antidepressants, with a recommended dose of sildenafil (50-100mg as needed) or tadalafil (10-20mg as needed, or 5mg daily) 2
  • Ensure patients are not taking nitrates, as it is an absolute contraindication due to dangerous blood pressure drops, and trial at least 5-8 separate occasions at maximum dose before declaring treatment failure 3, 4, 5
  • Tadalafil may be preferable given its longer duration of action (up to 36 hours), allowing more spontaneous sexual activity, and partner participation significantly improves outcomes, especially for orgasmic dysfunction 1, 4, 5, 6
  • The AUA/SMSNA guidelines recommend PDE5 inhibitors for orgasmic problems, with the strongest evidence supporting their use for antidepressant-induced sexual dysfunction 1, 2

Critical Considerations

  • Monitor depression symptoms closely when making any medication changes, as none of the sexual dysfunction management strategies studied showed worsening of psychiatric symptoms, though small sample sizes limit certainty 4
  • Ensure patients can perform moderate physical activity (walk 1 mile in 20 minutes) before starting PDE5 inhibitors, to avoid cardiovascular complications 5

Adjunctive Strategies for Escitalopram‑Induced Orgasmic Dysfunction

Medication Switch Considerations

  • In patients receiving escitalopram (10–20 mg daily) who experience orgasmic dysfunction, clinicians should weigh the risk of depression relapse before switching to another antidepressant, because escitalopram is providing therapeutic benefit at the current dose. 7

Non‑Pharmacologic Interventions

  • Vibratory therapy applied to the genital area has been shown to reduce difficulty achieving orgasm in individuals with antidepressant‑related sexual dysfunction. 8
  • Pelvic‑floor physical therapy improves overall sexual function in certain groups, with the strongest evidence observed in patients recovering from prostate surgery; it may also benefit those with medication‑induced orgasmic problems. 8